|
Canada-0-Insurance Azienda Directories
|
Azienda News:
- OpenEvidence
The leading medical information platform An Official AI Partner of The New England Journal of Medicine OpenEvidence content includes figures, tables, multimedia and full-text clinical findings from The New England Journal of Medicine
- OpenEvidence
The leading medical information platform
- About | OpenEvidence
An Official AI Partner of The New England Journal of Medicine OpenEvidence content includes figures, tables, multimedia and full-text clinical findings from The New England Journal of Medicine
- OpenEvidence Launches “Visits” : Real-Time Medical Intelligence for the . . .
OpenEvidence Visits is now live: a new feature purpose-built for the patient visit to deliver real-time evidence, help draft your clinical notes, and connect with patient context
- Announcements - OpenEvidence
The American Diabetes Association and OpenEvidence Collaborate to Accelerate Evidence-Based Guideline Delivery December 3, 2025
- OpenEvidence 2. 0 Now Available
We are excited to announce OpenEvidence 2 0 In addition to medical search, OpenEvidence now fully supports administrative and clinical workflow use cases, including:
- OpenEvidence AI becomes the first AI in history to score above 90% on . . .
OpenEvidence AI, the large language model-based artificial intelligence powering the automatic ingestion, analysis, synthesis, and research on openevidence com, has reached a new milestone as the first AI to score over 90% on the United States Medical Licensing Examination (USMLE) OpenEvidence makes 77% fewer errors on the US Medical Licensing Exam than ChatGPT, 24% fewer errors than GPT-4
- OpenEvidence and NEJM Group, publisher of the New England Journal of . . .
CAMBRIDGE, MA, February 19, 2025 – OpenEvidence, the fastest-growing platform for doctors, has signed a multi-year content agreement with NEJM Group, publisher of the New England Journal of Medicine (NEJM) Under this agreement, all published content and multimedia from 1990 forward from NEJM, NEJM Evidence, NEJM AI, NEJM Catalyst, and NEJM Journal Watch will be provided to OpenEvidence to
- National Organization for Rare Disorders and OpenEvidence Partner to . . .
NORWELL, Mass , and MIAMI, Fla (March 12, 2026) - The National Organization for Rare Disorders (NORD®) and OpenEvidence today announced a new partnership to expand access to trusted, expert-reviewed rare disease information for clinicians, patients and families
- OpenEvidence to Become a Mayo Clinic Platform Accelerate Company
OpenEvidence, an AI company pursuing foundational work in aligning Large Language Models (LLMs) to the medical domain, announced today it is to become a Mayo Clinic Platform Accelerate company As part of Mayo Clinic Platform Accelerate, OpenEvidence will collaborate with Mayo Clinic Platform to improve how health care information is structured and discovered
|
|